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AbsTrACT
background/aim To assess the treatment effect of 
0.1% ciclosporin A cationic emulsion (CsA CE) versus 
vehicle on signs/symptoms of dry eye disease (DED) in 
various subgroups (moderate-to-severe DED/severe DED/
Sjögren’s syndrome (SS)/SS with severe DED).
Methods Pooled data were analysed from two similar 
phase III studies: SICCANOVE (moderate-to-severe DED) 
and SANSIKA (severe DED with severe keratitis). In both 
studies, patients aged ≥18 years received CsA CE 0.1% 
(n=395) or vehicle (n=339) once daily for 6 months. 
A composite responder efficacy endpoint (corneal 
fluorescein staining–Ocular Surface Disease Index (CFS–
OSDI) at month 6) was used to evaluate the efficacy of 
CsA CE in alleviating signs/symptoms of DED (response 
defined as improvement of ≥2 grades in CFS and 
≥30% in OSDI (baseline to month 6)). Human leucocyte 
antigen-DR (HLA-DR) conjunctival expression was used 
as a biomarker of ocular surface inflammation.
results CsA CE–treated patients were significantly 
more likely to be CFS–OSDI responders than vehicle-
treated patients in the overall (OR 1.66, 95% CI 1.11 
to 2.50; P=0.015), severe DED (1.80, 1.04 to 3.19; 
P=0.038) and SS with severe DED (3.37, 1.20 to 11.19; 
P=0.030) populations. The difference was not significant 
for CsA CE versus vehicle for the overall Sjögren’s 
population (OR 1.77, CI 0.89 to 3.66; P=0.109). CsA 
CE also significantly reduced median HLA-DR expression 
versus vehicle at 6 months (P=0.002).
Conclusion Pooled phase III data indicate CsA CE 
produced significant improvement in signs/symptoms 
versus vehicle in patients with moderate-to-severe DED 
(especially in those with severe keratitis), including 
patients with SS with severe DED.
InTroduCTIon
The Dry Eye Workshop II has recently proposed a 
new definition of dry eye disease (DED): DED is 
a multifactorial disease of the ocular surface char-
acterised by a loss of homeostasis of the tear film, 
and accompanied by ocular symptoms, in which 
tear film instability and hyperosmolarity, ocular 
surface inflammation and damage, and neurosen-
sory abnormalities play aetiological roles.1 DED 
affects 5%–50% of the population according to 
worldwide surveys,2 and patients can experience 
debilitating effects, both physically and psycholog-
ically, from ocular pain and irritative symptoms; 
difficulties performing basic activities of daily living 
such as driving and using a computer; and visual 
problems such as blurry vision.2 3 Management of 
DED is complicated by the fact that it is driven by 
a self-perpetuating vicious cycle of tear film insta-
bility, hyperosmolarity and ocular surface inflam-
mation.4 5 Without treatment, DED can progress 
and increase in severity, becoming more refractory 
to treatment and potentially leading to permanent 
ocular damage.4 6
Current treatment strategies typically rely on 
the use of artificial tears to lubricate and hydrate 
the ocular surface, but this approach provides 
only short-term symptomatic relief that does 
not address ocular surface inflammation, the 
principal underlying pathophysiological compo-
nent of chronic DED.7 8 Ciclosporin A (CsA), 
an anti-inflammatory agent, has shown signif-
icant benefits in moderate-to-severe DED and 
has been the focus of increasing interest and 
investigation in recent years.9 When applied 
topically as an oil-based formulation, CsA has 
low bioavailability and is poorly tolerated10; 
however, in 2015, a cationic emulsion (CE) 
formulation containing 0.1% (1 mg/mL) CsA 
(CsA CE; Ikervis; Santen SAS, Evry, France) was 
approved by the European Medicines Agency for 
the treatment of severe keratitis in adults with 
DED that has not improved despite treatment 
with tear substitutes. Compared with previ-
ously available formulations of CsA, CsA CE 
has a prolonged precorneal residence time and 
improved bioavailability, allowing for once-
daily instillation.11–14 The efficacy and safety of 
CsA CE were assessed in two double-masked, 
randomised, parallel-group, vehicle-controlled 
phase III studies: SICCANOVE, in patients with 
moderate-to-severe DED; and SANSIKA, in 
patients with severe DED. Overall, CsA CE was 
well tolerated and efficacious in reducing corneal 
surface damage and ocular surface inflammation 
in patients with moderate-to-severe DED.15–17
Pooled data from the SICCANOVE and 
SANSIKA studies were analysed to better under-
stand the magnitude of the treatment effect of CsA 
CE, compared with vehicle, on signs and symptoms 
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Table 1 Demographic and baseline characteristics of patients 
included in the pooled full analysis set
CsA CE (n=395) Vehicle (n=339)
SANSIKA study (n, %) 154 (39.0) 91 (26.8) 
SICCANOVE study (n, %) 241 (61.0) 248 (73.2)
Mean age, years (SD) 58.7 (13.2) 59.5 (12.5)
Female, n (%) 331 (83.8) 291 (85.8)
Sjögren’s syndrome, n (%) 147 (37.2) 122 (36.0)
Severe DED, n (%)
(CFS grade 4, OSDI ≥23)
193 (48.9) 126 (37.2)
HLA-DR data available, n (%) 94 (23.8) 74 (21.8)
CFS, mean (SD)—SANSIKA study 4.00 (0.00)
(n=154)
4.00 (0.00)
(n=90)
CFS, mean (SD)—SICCANOVE study 2.83 (0.71)
(n=241)
2.80 (0.72)
(n=248)
OSDI, mean (SD)—SANSIKA study 61.4 (19.4)
(n=154)
58.8 (18.4)
(n=91)
OSDI, mean (SD)—SICCANOVE study 44.41 (21.94)
(n=241)
41.96 (21.84)
(n=248)
CFS, corneal fluorescein staining; CsA CE, 0.1% (1 mg/mL) ciclosporin A cationic 
emulsion; DED, dry eye disease; HLA-DR, human leucocyte antigen-DR; OSDI, Ocular 
Surface Disease Index.
of DED in the overall DED population and in multiple patient 
subgroups defined by age, sex, menopausal status, disease 
severity or duration and the presence or absence of Sjögren’s 
syndrome (SS).
METhods
study design and participants
Data for this pooled analysis were obtained from two 
randomised, 6-month phase III clinical studies (EudraCT 
numbers: 2007-000029-23 (SICCANOVE), 2011-000160-97 
(SANSIKA)) that evaluated the efficacy and safety of CsA CE 
in patients with moderate-to-severe DED.15 16 Both studies 
were conducted in accordance with the principles of Good 
Clinical Practice and with the ethical principles set out in the 
Declaration of Helsinki. All enrolled patients provided written 
informed consent. Efficacy and safety methods and results 
from each study have been previously described15 16; the design 
of both studies is outlined in online supplementary figure 1 and 
briefly described below.
The SICCANOVE and SANSIKA studies were similar in 
design, allowing the data to be pooled for analysis. Both 
were multicentre, double-masked, parallel-group, controlled 
studies conducted in Europe in which patients ≥18 years 
of age with DED were randomised to receive once-daily 
CsA CE 0.1% (1 mg/mL) or its vehicle for 6 months. The 
SICCANOVE study included patients with moderate-to-se-
vere DED (in the same eye: ≥1 symptom of ocular discom-
fort with a severity score ≥2 (on a 4-point scale), tear 
breakup time ≤8 s, corneal fluorescein staining (CFS) score 
between 2 and 4 (modified Oxford scale; 0 to 5), Schirmer 
test without anaesthesia ≥2 mm/5 min and <10 mm/5 min, 
and corneal/conjunctival lissamine green staining score ≥4 
(van Bijsterveld scale)).16 The SANSIKA study enrolled 
patients with severe DED (CFS=4 (modified Oxford scale; 
0 to 5), Schirmer test without anaesthesia ≥2 mm/5 min 
and <10 mm/5 min, and Ocular Surface Disease Index 
(OSDI) score ≥23).15 All patients who received active treat-
ment or vehicle in the SICCANOVE and SANSIKA studies 
were included in the pooled analysis.
study assessments and endpoints
Both studies included objective assessments of DED signs, such 
as CFS score and Schirmer test, as well as subjective assessments 
of DED symptoms, such as OSDI and visual analogue scales, 
which assessed patient symptoms (burning or stinging, foreign 
body sensation, itching, eye dryness, pain, blurred vision, sticky 
feeling and photophobia). Efficacy was determined only in the 
analysis eye, defined as the worst eye meeting the entry criteria 
listed above. The primary efficacy endpoint in the pooled anal-
ysis was a composite responder efficacy endpoint (CFS–OSDI) 
at month 6, defined as an improvement in both CFS (modi-
fied Oxford scale) by ≥2 grades from baseline and OSDI score 
by ≥30%. Human leucocyte antigen-DR (HLA-DR) expres-
sion on conjunctival epithelial cells (as assessed by impression 
cytology) at baseline and at month 6 was evaluated to investigate 
the relationship between disease severity (CFS score) and ocular 
surface inflammation.
Ocular and systemic adverse events were monitored 
throughout the SICCANOVE and SANSIKA studies (baseline 
visit through month 6 visit). Other safety assessments included 
best-corrected distance visual acuity (BCDVA), intraocular pres-
sure (IOP) and blood sampling of systemic CsA levels.
statistical analyses
CFS–OSDI responder rates were analysed with a logistic regres-
sion model (with ‘treatment’ and ‘pooled country’ as factors) 
using imputed data. Study effect was included as a fixed effect 
to account for the structure of the data set. The CFS–OSDI 
responder rate was analysed in four patient populations: (1) all 
DED patients (full analysis set (FAS); n=734), (2) severe DED 
(n=319; patients with CFS grade 4 and OSDI ≥23), (3) all 
SS patients (n=269; patients with SS) and (4) SS/severe DED 
(n=130; patients with SS and severe DED). Sensitivity analyses 
for CFS–OSDI responder rates were performed using the main 
logistic model on the per-protocol set, on the FAS (observed 
data) and on the FAS by treatment received. Sensitivity analyses 
were also performed using the Cochran-Mantel-Haenszel test 
and controlling for pooled country.
CFS measurements (changes from baseline to month 6) were 
analysed by age, sex, menopausal status, SS status and disease 
duration in a subset of patients (n=629) who had CFS values at 
baseline and at month 6. The model was adjusted for treatment, 
study, visit and treatment by study. HLA-DR data were analysed 
after logarithmic transformation using an analysis of covariance 
model with ‘treatment’ and ‘pooled country’ as fixed factors and 
baseline score as a covariate. Because the data distribution for 
HLA-DR expression was found to be log-normal, median, rather 
than mean, values were reported as a measure of location.
rEsulTs
study population
The pooled FAS (all DED patients) population included 734 
patients (table 1), 395 CsA CE patients and 339 vehicle patients. 
Most of the patients (84.7%) were women, 43.5% had severe 
DED and 36.6% had SS. Overall, demographic and baseline 
disease characteristics were well balanced across treatment 
groups.
Co-responder analysis
Patients treated with CsA CE were more likely to be CFS–
OSDI responders than patients treated with vehicle (figure 1). 
In the FAS (all DED patients) population, 21.6% of CsA CE 
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Figure 1 CFS–OSDI responder rates in the pooled analysis. *Statistically significant difference for CsA CE versus vehicle (P<0.05). Values represent 
imputed data. The P values were calculated using a logistic regression model. CFS, corneal fluorescein staining; CsA CE, 0.1% (1 mg/mL) ciclosporin A 
in a cationic emulsion; DED, dry eye disease; FAS, full analysis set; OSDI, Ocular Surface Disease Index.
Figure 2 Pooled analysis and individual study results for the effect of CsA CE in improving both signs and symptoms (assessed by CFS–OSDI 
responder rate) in (A) all patients, (B) patients with severe DED, (C) all patients with SS and (D) patients with SS and severe DED at baseline. 
A response was defined as improvement of ≥2 grades in CFS and ≥30% in OSDI. CFS, corneal fluorescein staining; CsA CE, 0.1% (1 mg/mL) 
ciclosporin A in a cationic emulsion; DED, dry eye disease; FAS, full analysis set; OSDI, Ocular Surface Disease Index; SS, Sjögren’s syndrome.
patients achieved a CFS–OSDI response, compared with 13.1% 
of patients treated with vehicle (P=0.015). In the subgroup 
of patients with severe DED at baseline, 29.5% of patients 
with CsA CE achieved a CFS–OSDI response, compared with 
18.3% of vehicle patients (P=0.038). In the overall SS group, 
differences were not statistically significant: 19.2% of CsA CE 
patients achieved a CFS–OSDI response, compared with 11.6% 
of vehicle patients (P=0.109). However, statistical significance 
was reached in the subgroup of patients with SS with severe 
DED (23.4% for CsA CE patients vs 9.4% for vehicle patients; 
P=0.030).
The ORs for CFS–OSDI response for the individual 
and combined studies illustrate the same trends, favouring 
CsA CE treatment over vehicle except in the overall SS 
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Figure 3 Change from baseline in CFS score at month 6 by patient subgroup in the pooled analysis (n=629). Green boxes represent the estimate 
of the difference between groups (least-squares means). Horizontal lines are 95% confidence limits. CFS, corneal fluorescein staining; CL, confidence 
limit; CsA CE, 0.1% (1 mg/mL) ciclosporin A in a cationic emulsion; LCL, lower confidence limit; UCL, upper confidence limit; VEH, vehicle.
population (figure 2A–D). In the FAS (all DED patients) 
population (figure 2A), the OR and the 95% CI were 1.66 
(1.11 to 2.50), and in the subgroup of patients with severe DED, 
the corresponding values were 1.80 (1.04 to 3.19) (figure 2B). 
The OR and 95% CI in the SS/severe DED population also 
favoured CsA CE treatment and indicated a three-times-greater 
probability of response over vehicle in this patient population 
(OR 3.37; 1.20 to 11.19) (figure 2D).
Corneal fluorescein staining
Improvements in CFS score at month 6 favoured CsA CE over 
vehicle in the overall population (treatment difference –0.303; 
95% confidence limit (CL) –0.464 to –0.142) (figure 3). A 
significant treatment effect in favour of CsA CE was observed 
in most patient subgroups in the pooled analysis. Clinical benefit 
with CsA CE was most notable in elderly patients (65–74 
years of age: treatment difference –0.568, 95% CL –0.897 to 
–0.239; ≥75 years of age: –0.569, –1.085 to –0.053), female 
patients (–0.349, –0.527 to –0.171) and menopausal patients 
(–0.433, –0.638 to –0.228). Treatment with CsA CE also 
produced improvements in CFS score regardless of SS status (SS 
–0.288, –0.559 to –0.017; no SS –0.321, –0.520 to –0.123).
ocular surface inflammation and relationship to dEd severity
For the 168 patients with HLA-DR data at baseline and month 6, 
baseline HLA-DR expression values were directly proportional 
to CFS score, indicating that patients with more severe DED 
had increased ocular inflammation. Figure 4 shows change in 
HLA-DR expression in median arbitrary units of fluorescence 
according to baseline CFS score subgroups (CFS=2, 3 or 4). 
Overall, CsA CE was significantly more effective versus vehicle 
in reducing ocular inflammation from baseline to month 6 
(P=0.002). Notably, while reductions in HLA-DR expression 
were observed with CsA CE for each CFS subgroup, and to a 
lesser extent for vehicle with the CFS=2 and CFS=4 subgroups, 
an increase in HLA-DR expression was seen among patients 
receiving vehicle in the CFS=3 subgroup.
safety findings
Drug-related treatment-emergent adverse events (TEAEs) were 
reported in 35.9% of CsA CE patients and 20.3% of vehicle 
patients in the pooled analysis (online supplementary table 
1). Drug-related TEAEs were mostly ocular in nature, with 
no reported incidence of serious systemic events. The most 
frequently reported ocular TEAEs deemed possibly related to 
CsA CE treatment were instillation site pain (12.1%), eye irrita-
tion (10.1%) and instillation site irritation (5.1%). Two patients 
experienced serious drug-related ocular TEAEs: one patient in 
the CsA CE group had severe corneal epithelial erosion that 
resolved without sequelae, and one patient in the vehicle group 
had decreased BCDVA; both discontinued therapy. Overall, study 
discontinuation due to drug-related ocular TEAEs was reported 
in 9.3% of CsA CE patients and 5.9% of vehicle patients.
There were no clinically significant changes in blood pressure, 
pulse rate or respiratory rate in either treatment group during the 
6-month course of the studies; BCDVA and IOP also remained 
stable. At baseline, five patients presented with a serum CsA 
value greater than the upper limit of quantification (5.0 mg/mL; 
ie, CsA levels that could be reliably quantified); these patients 
were already receiving systemic CsA at a stable dose (as allowed 
by the study protocols). At the month 6 visit, 35 patients had 
a detectable serum CsA level that was below the upper limit 
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Figure 4 Pooled analysis of the relationship between CFS score and HLA-DR expression (as assessed by impression cytology). AUF, arbitrary units of 
fluorescence; CFS, corneal fluorescein staining; CsA CE, 0.1% (1 mg/mL) ciclosporin A in a cationic emulsion; HLA-DR, human leucocyte antigen-DR.
of quantification (ie, CsA levels that could be detected but not 
reliably quantified), and 11 patients had a quantifiable serum 
value; the latter values were considered negligible (highest value 
0.206 ng/mL).
dIsCussIon
This analysis of pooled data from the SICCANOVE and SANSIKA 
studies provides a representative estimation of the efficacy and 
safety of CsA CE in the treatment of moderate-to-severe DED. 
CsA CE was statistically superior to vehicle in improving both 
signs and symptoms of DED in the overall patient population 
(especially in those with severe keratitis) and in patients with SS/
severe DED, and there was a trend towards greater benefits in 
the overall Sjögren’s population; CsA CE also demonstrated a 
safety profile consistent with ophthalmic CsA use.
Results in this pooled analysis were generally consistent with 
those in the SANSIKA study, which used the composite CFS–
OSDI response rate as its primary signs and symptoms endpoint. 
The SANSIKA study found a CFS–OSDI response rate of 
28.6% in the CsA CE group and 23.1% in the vehicle group 
(P=0.326).15 Although statistical significance was not achieved 
for CsA CE compared with vehicle in SANSIKA, it should 
be noted that statistical significance was achieved when the 
threshold for improvement of CFS was increased from 2 grades 
to 3 grades in a post hoc analysis.15 Lack of statistical significance 
for the primary endpoint in the SANSIKA study may have been 
due to the marked improvement seen with the vehicle, which 
is an unpreserved cationic oil-in-water nanoemulsion that can 
have a beneficial effect on DED symptoms through improved 
lubrication and hydration.14 18 Discordance between signs and 
symptoms of DED has been a challenge in the conduct of DED 
studies.19–21 In this respect, the composite endpoint provides a 
useful joint assessment of signs and symptoms in such a multi-
faceted disease; this approach has also been proposed in other 
chronic inflammatory diseases (eg, fibromyalgia, rheumatoid 
arthritis).22
The results for CFS change from baseline in this pooled anal-
ysis were consistent with those obtained in both studies; a mean 
treatment difference between CsA CE and vehicle of –0.303 (95% 
CL –0.464 to –0.142) was observed for the overall patient popu-
lation in the pooled analysis, as compared with a mean treatment 
difference of –0.22 (95% CI –0.39 to –0.06) and –0.35 (95% CI 
–0.671 to –0.021) in SICCANOVE and SANSIKA, respectively; 
all results were statistically significant.15 16 According to the 
logarithmic nature of the modified Oxford scale, these findings 
correspond to 30%–50% more punctate epithelial damage of 
the cornea in the vehicle group versus the treatment groups. The 
improvement observed with CsA CE, particularly in the more 
severe populations, supports the primary goal for treatment of 
moderate-to-severe DED─namely, to maintain and protect the 
ocular surface.23
CsA CE also improved signs and symptoms (as assessed by 
CFS–OSDI response) in patients with SS, although the superi-
ority over vehicle was statistically significant only in the subset 
of patients with both SS and severe DED. These findings are of 
importance, given that DED in patients who have SS, an auto-
immune form of aqueous-deficient dry eye, is typically more 
severe and difficult to treat than in patients without SS.24 25 A 
clear association between ocular surface inflammation (HLA-DR 
expression as assessed by conjunctival impression cytology) and 
DED severity was also observed,26 and CsA CE significantly 
reduced HLA-DR expression compared with vehicle at month 
6 (overall treatment difference: P=0.002). This effect of CsA 
CE on HLA-DR likely derives from CsA CE’s anti-inflammatory 
properties,26–28 and results from this pooled analysis support the 
use of HLA-DR expression level as a biomarker to monitor treat-
ment response in patients with DED.
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Limitations of this pooled analysis include differences in 
entry criteria for the two studies (moderate-to-severe DED for 
SICCANOVE vs severe DED for SANSIKA), which may limit 
comparability of the results. However, it should be noted that 
when applying the ODISSEY algorithm for establishing the 
severity of DED,29 both populations are categorised as predom-
inantly having severe disease (86.5% in SICCANOVE and 98% 
in SANSIKA at baseline).30 Interestingly, from a geographical 
perspective, the two studies were conducted in Europe in the 
same countries (Spain, France, UK, Italy, Czech Republic and 
Germany) and many of the same clinical centres, with the excep-
tion that SANSIKA also recruited patients in Austria and Belgium. 
Moreover, the recruitment was conducted over multiple months 
for both studies (18 months for SICCANOVE and 10 months 
for SANSIKA) in order to avoid biases from seasonal and weath-
er-related conditions.31
In conclusion, the combined efficacy and safety data from this 
pooled analysis suggest that CsA CE—a novel formulation of 
unpreserved single-dose cationic emulsion of ciclosporin  0.1%—
has a favourable safety and tolerability profile and is efficacious 
in improving both signs and symptoms of DED in patients with 
moderate-to-severe DED (especially those with severe keratitis), 
including patients with SS with severe DED.
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